AGC Biologics, a provider of clinical and commercial manufacturing of therapeutic proteins, said that their development and manufacturing capabilities at their Seattle, WA and Copenhagen, Denmark facilities will be expanded.
 
These state of the art facility upgrades, which are expected to begin in the second and third quarters of 2020, aim to eliminate bottlenecking and allow for capacity expansion. The Seattle investment will strengthen service from the clinical through commercial phases and includes a 500-liter mammalian cell bioreactor. The Copenhagen investment will enable the site to increase capacity and includes a new purification line.
 
The total investment is expected to be around $18 million.